2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma: A bicenter trial

Cancer

Volumn 91, Issue 5, 2001, Pages 889-899

  Buchmann, Inga ^a   Reinhardt, Michael ^b   Elsner, Klaus ^a   Bunjes, Donald ^a   Altehoefer, Carsten ^b   Finke, Jürgen ^b   Moser, Ernst ^b   Glatting, Gerhard ^a   Kotzerke, Jörg ^a   Guhlmann, Carl A ^a   Schirrmeister, Holger ^a   Reske, Sven N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

2 (fluorine 18)fluoro 2 deoxy D glucose; Detection; Initial staging; Lymphoma; M. Hodgkin; Non Hodgkin lymphoma; Positron emission tomography; Upstaging.

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOPAMIDOL;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES; BIOPSY; BONE MARROW; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0035281784     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5     Document Type: Article

References (46)

1. On the origin of cancer cells
2. [F-18]-FDG-PET for differential diagnosis of pleural processes
3. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall lung carcinoma
4. Detection of unknown occult primary tumors using positron emission tomography
5. Lymphoma: Role of whole-body 2-deoxy-2-(F-18)-fluoro-D-glucose (FDG) PET in nodal staging
6. Detection of extranodal malignant lymphoma with positron emission tomography using fluorine-18-fluorodeoxyglucose (FDG-PET): Comparison with computed tomography (CT)
7. Positron Emission Tomography (PET) for detection and staging of malignant lymphoma
8. Whole-body 2-[18-F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease
9. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow
10. Detection of lymphoma in bone marrow by whole-body positron emission tomography
11. Late complications after Hodgkin's disease
12. Lymphoma classification - The gap between biology and clinical management is closing
13. Non-Hodgkin's lymphoma
14. Treatment, patterns of failure, survival of patients with Stage I nodal and extranodal non-Hodgkin's lymphomas, according to data in the population-based registry of the Comprehensive Cancer Centre West
15. Hodgkin's disease: Complications of therapy and excess mortality
16. A randomized comparison of the efficacy and toxicity, of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma
17. New classification for non-Hodgkin's lymphoma
18. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma
19. PISAC: A postinjection method for segmented attenuation correction in whole-body PET
20. Improved iterative image reconstruction using variable projection binning and abbreviated convolution
21. A method of comparing the areas tinder receiver operating characteristic curves derived from the same cases
22. A multivariate analysis of the survival of patients with aggressive lymphoma: Variations in the predictive value of prognostic factors during the course of the disease
23. Mediastinum
24. Upper abdominal lymph node size determined with CT
25. Abdominal lymphadenopathy: Spectrum of CT findings
26. Bronchogenic carcinoma: Incidence of metastases to normal sized lymph nodes
27. Bronchogenic carcinoma metastatic to normal-sized nodes: Frequency and significance
28. Bimage sonography in lymph node staging of the head and neck area: A comparison with palpation, computerized and magnetic resonance tomography
29. CT of lymphoma: Spectrum of disease
30. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkins' disease
31. Computed tomography, lymphangiography and staging laparotomy: Correlations in initial staging of Hodgkin's disease
32. Comparison of lymphangiography and computed tomography scanning in evaluation abdominal disease in Stages III and IV Hodgkins' disease
33. Lymphoma of the solid abdominal viscera
34. Diagnostic imaging studies in patients with newly diagnosed Hodgkins' disease
35. Malignant lymphoma of the spleen: A review of 49 cases in which the diagnosis was made at splenectomy
36. The liver in Hodgkins' disease: II. Histopathologic findings
37. Imaging techniques for staging abdominal Hodgkin's disease
38. Magnetic resonance imaging in the initial staging of Hodgkin's disease and non-Hodgkin's lymphoma
39. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease?
40. The bone marrow manifestations of Hodgkin's disease, the non-Hodgkin's lymphomas, and lymphoma-like disorders
41. The staging of non-Hodgkin's lymphoma
42. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging
43. Analytical decision model for the cost-effective management of solitary pulmonary nodules
44. Whole-body FD-PET imaging for staging of Hodgkin's disease and lymphoma
45. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose